Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

First patient, first visit is planned for early June 2024Enrollment has been expanded by 80% to a maximum of 180 participants‘Real-world' drug efficacy data will be collected by monitoring potential drug effects on survival and disease progression, as well as safety SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondri ...